elapsed_time: 19s
was_input_captured: True
original_text: |
    Has had prior chemotherapy or targeted small molecule therapy within 2 weeks prior to start of treatment or has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; previous radiation to extracranial sites may be completed at any time prior to initiation of pembrolizumab;
    * Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
    * Note: Toxicity that has not recovered to =< grade 1 is allowed if it meets the inclusion requirements for laboratory parameters
inclusion: False
